Develop psychedelic-based therapeutics for mental health conditions. Focus on deuterated psychedelic compounds for improved efficacy. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 41% a year over the last 3 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1,702.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 20% of them.
Analysts' average target sits 20% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Sales run at $472K a year. A small number, but proof the product has real buyers.
A loss of $113.1M against $472K in annual sales.
At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.
On our five-subject report card, HELP sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: HELP is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (20/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown, the price history.